CytomX Therapeutics, ImmunoGen Announce Strategic Collaboration

CytomX Therapeutics and ImmunoGen

today announced a multi-year, strategic collaboration to develop Probody-drug conjugate (PDC) therapies for the treatment of cancer. Probodies are a potentially disruptive class of antibody therapeutics that may further broaden the opportunities for ADCs by localizing therapeutic activity to the tumor microenvironment.